射频STRETTA在初次抗反流术后复发及初次STRETTA后复发的GERD中的作用
本回顾性研究评估STRETTA对两类复发GERD患者的作用:初次抗反流手术(ARS)后结构完整但症状复发者(OP to STR,13例)及初次STRETTA成功后复发者(STR to STR,6例)。OP to STR组RSI和QoL显著改善,STR to STR组无统计学显著改善,两组PPI使用无显著差异。
要点
- 初次ARS后复发GERD患者接受STRETTA可显著改善反流症状和生活质量。
- 初次STRETTA成功后复发者再次STRETTA未见统计学显著获益。
- 两组质子泵抑制剂使用在STRETTA前后无统计学显著差异。
核心结论
- 初次ARS后复发的GERD患者接受STRETTA后RSI和QoL显著改善。
- 初次STRETTA后复发者再次STRETTA在RSI和QoL上无统计学显著改善。
- 两组STRETTA前后PPI使用无统计学显著差异。
研究设计与样本
- 回顾性研究,纳入2014至2024年单中心接受STRETTA的患者共19例。
- OP to STR组13例,STR to STR组6例,使用经验证的RSI和GERD HRQL问卷评估。
主要发现
- OP to STR组RSI显著下降(Wilcoxon V=84.5,p=0.007),QoL显著改善(Wilcoxon V=66,p=0.004)。
- STR to STR组RSI无统计学显著改善(Wilcoxon V=15,p=0.058),QoL亦无(Wilcoxon V=19,p=0.093)。
- ARS至STRETTA中位时间8.7年,STR to STR组5.5年,p=0.180。
- OP to STR组中位随访5.7年,STR to STR组0.8年,p=0.008。
- 中位年龄OP to STR组66.0岁,STR to STR组54.5岁。
临床怎么用
- 对于初次ARS后结构完整但症状复发的GERD患者,STRETTA可作为可选的无创治疗。
- 初次STRETTA后复发者再次STRETTA的获益尚不明确,需个体化决策。
局限性
- 回顾性、小样本(19例)、单中心研究,结果需更大规模稳健研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gastroesophageal reflux disease (GERD) is a common chronic condition affecting millions all over the world. It occurs due to the reflux of gastric acid into the oesophagus. Endoscopic therapies like STRETTA offer minimally invasive options to manage GERD. This study aims to evaluate the role of STRETTA in patients with recurrent symptoms after structurally intact hiatus hernia repair with anti-reflux surgery (ARS) and in patients who had an initially successful STRETTA. METHODS: A retrospective review was conducted on patients who underwent STRETTA from 2014 to 2024 at a tertiary centre to identify patients whose STRETTA therapy followed either a primary ARS (OP to STR) or primary STRETTA (STR to STR). Patients' outcomes were assessed before and after the STRETTA procedure using validated RSI (Reflux symptom index), and GERD HRQL (Gastro Esophageal Reflux Disease Health-Related Quality of Life) quality of life (QoL) questionnaires. The use of anti-secretory medications was analysed using Chi-Square (X2) test. RESULTS: 19 eligible patients were studied under 2 cohorts: 13 underwent STRETTA following a primary ARS (OP to STR) and 6 had a repeat STRETTA following a primary successful STRETTA (STR to STR). The median time from ARS to STRETTA was 8.7 years compared with 5.5 years in the STR to STR group, p = 0.180. The median follow-up in the ARS to STR group was significantly longer at 5.7 years compared to 0.8 years in the STR to STR, p = 0.008. The median age was 66.0 years in ARS to STRETTA group and 54.5 years in the STR to STR cohort. The OP to STR cohort saw a significant reduction in the RSI (Wilcoxon V = 84.5, p = 0.007) and improvement in QoL (Wilcoxon V = 66, p = 0.004). The STR to STR cohort did not show a statistically significant improvement in either RSI (Wilcoxon V = 15, p = 0.058) or QoL scores (Wilcoxon V = 19, p = 0.093). No statistically significant difference was noted in the usage of PPIs in either cohort. CONCLUSION: This retrospective, small sample and single-centre study opens the debate about the role of endoscopic radiofrequency STRETTA therapy in selected recurrent GERD patients following successful primary ARS. Furthermore, though our limited data showed no statistically significant benefit in RSI and GERD HRQL for the STR to STR cohort, this is a compelling topic which begs for larger robust studies.
引用
- Viswanath YKS, Mbarushimana S, Ammar A, et al. Role of radiofrequency STRETTA for recurrent GERD following primary anti-reflux surgery and primary STRETTA therapy. Surg Endosc. 2025. PMID: 40425859. doi:10.1007/s00464-025-11781-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。